WO2014116097A3 - Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox - Google Patents

Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox Download PDF

Info

Publication number
WO2014116097A3
WO2014116097A3 PCT/MX2014/000029 MX2014000029W WO2014116097A3 WO 2014116097 A3 WO2014116097 A3 WO 2014116097A3 MX 2014000029 W MX2014000029 W MX 2014000029W WO 2014116097 A3 WO2014116097 A3 WO 2014116097A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
compound
compositions
oxidative stress
pathological conditions
Prior art date
Application number
PCT/MX2014/000029
Other languages
English (en)
French (fr)
Other versions
WO2014116097A2 (es
Inventor
Gabriel GOJON ROMANILLOS
Original Assignee
Nuevas Alternativas Naturales Thermafat, S.A.P.I. De C.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/751,429 external-priority patent/US20130136725A1/en
Priority to MX2015009403A priority Critical patent/MX2015009403A/es
Priority to BR112015017440A priority patent/BR112015017440A2/pt
Priority to EP14743853.5A priority patent/EP2949332A4/en
Priority to CN201480018525.6A priority patent/CN105228633A/zh
Priority to AU2014210447A priority patent/AU2014210447A1/en
Application filed by Nuevas Alternativas Naturales Thermafat, S.A.P.I. De C.V. filed Critical Nuevas Alternativas Naturales Thermafat, S.A.P.I. De C.V.
Priority to CA2898596A priority patent/CA2898596A1/en
Priority to JP2015555120A priority patent/JP2016508996A/ja
Priority to KR1020157023387A priority patent/KR20160140331A/ko
Publication of WO2014116097A2 publication Critical patent/WO2014116097A2/es
Publication of WO2014116097A3 publication Critical patent/WO2014116097A3/es
Priority to HK16105188.3A priority patent/HK1217175A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Alteraciones de homeostasis redox en mamíferos forman la base de un número de síntomas, síndromes y enfermedades, incluyendo SIDA y cáncer, los cuales pueden ser tratados exitosamente por administración a un mamífero de cantidades terapéuticamente efectivas de compuestos de sulfuro y/o compuestos de tiosulfato y/o compuestos de tionita y/o compues¬ tos de tionato y/o especies químicas capaces de proporcionar a un sujeto en necesidad de ello un compuesto de sulfuro, compuesto de tiosulfato, compuesto de tionita, o compuesto de tionato. Las composiciones únicas de esta invención contienen una o más "sustancias de azufre activo" en combinación entre sí o con otros agentes terapéuticos. La invención también abarca los modos de administración variables de las sustancias terapéuticas. En particular, un método novedoso para combinar ingredientes activos con celulosa húmeda se proporciona, el cual permite que la celulosa húmeda funcione como un vehículo entérico.
PCT/MX2014/000029 2013-01-28 2014-01-28 Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox WO2014116097A2 (es)

Priority Applications (9)

Application Number Priority Date Filing Date Title
KR1020157023387A KR20160140331A (ko) 2013-01-28 2014-01-28 산화 스트레스 및/또는 산화환원 불균형으로부터 야기되는 병리학적 상태의 전신 치료를 위한 조성물
BR112015017440A BR112015017440A2 (pt) 2013-01-28 2014-01-28 composições para o tratamento sistêmico de condições patológicas resultantes do stress oxidante e/ou do desequilíbrio de redox
EP14743853.5A EP2949332A4 (en) 2013-01-28 2014-01-28 COMPOSITIONS FOR THE SYSTEMATIC TREATMENT OF PATHOLOGICAL CONDITIONS RELATED TO OXIDATIVE STRESS AND / OR REDOX DISBALANCE
CN201480018525.6A CN105228633A (zh) 2013-01-28 2014-01-28 用于由氧化应激和/或氧化还原失衡产生的病理状态的全身治疗的组合物
AU2014210447A AU2014210447A1 (en) 2013-01-28 2014-01-28 Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
MX2015009403A MX2015009403A (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistemico de condiciones patologicas resultantes de estres oxidativo y/o desequilibrio redox.
CA2898596A CA2898596A1 (en) 2013-01-28 2014-01-28 Compositions for the systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance
JP2015555120A JP2016508996A (ja) 2013-01-28 2014-01-28 酸化ストレス及び／又は酸化還元不均衡の結果生じる病的状態の全身的治療のための組成物
HK16105188.3A HK1217175A1 (zh) 2013-01-28 2016-05-06 用於由氧化應激和/或氧化還原失衡產生的病理狀態的全身治療的組合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/751,429 2013-01-28
US13/751,429 US20130136725A1 (en) 2002-06-19 2013-01-28 Compositions for systemic treatment of pathological conditions resulting from oxidative stress and/or redox imbalance

Publications (2)

Publication Number Publication Date
WO2014116097A2 WO2014116097A2 (es) 2014-07-31
WO2014116097A3 true WO2014116097A3 (es) 2014-12-04

Family

ID=51228167

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/MX2014/000029 WO2014116097A2 (es) 2013-01-28 2014-01-28 Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox

Country Status (10)

Country Link
EP (1) EP2949332A4 (es)
JP (1) JP2016508996A (es)
KR (1) KR20160140331A (es)
CN (1) CN105228633A (es)
AU (1) AU2014210447A1 (es)
BR (1) BR112015017440A2 (es)
CA (1) CA2898596A1 (es)
HK (1) HK1217175A1 (es)
MX (1) MX2015009403A (es)
WO (1) WO2014116097A2 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7424972B2 (ja) 2017-10-25 2024-01-30 ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用
TWI760682B (zh) * 2019-01-19 2022-04-11 紅嬰生物科技股份有限公司 眼用透鏡、藥學組合物及其用途
EP3922993A1 (en) 2020-06-12 2021-12-15 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
EP4121763A1 (en) 2020-03-16 2023-01-25 4TEEN4 Pharmaceuticals GmbH Dpp3 in patients infected with coronavirus
WO2024126793A1 (en) 2022-12-15 2024-06-20 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for improvement of pulmonary function in critically ill patients
WO2024200862A1 (en) 2023-03-29 2024-10-03 4TEEN4 Pharmaceuticals GmbH Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
JPS59118709A (ja) 1982-12-27 1984-07-09 Suntory Ltd 効力を増強しかつ低毒化せしめた抗腫瘍組成物
DE3419686A1 (de) 1983-05-26 1984-11-29 T and R Chemicals, Inc., Clint, Tex. Verwendung einer zusammensetzung mit therapeutischer wirksamkeit
IL81166A (en) 1987-01-05 1990-03-19 Kaplan Ephraim Pharmaceutically active combination comprising an ionic vanadium compound and thiosulfate or sulfite compound and optionally selenium
JP5063878B2 (ja) * 2005-08-30 2012-10-31 扶桑薬品工業株式会社 硫化水素塩を含有する消化器系疾患の予防／治療用組成物
EP3213756A1 (en) * 2009-07-08 2017-09-06 Hope Medical Enterprise, Inc. D.b.a. Hope Pharmaceuticals Sodium thiosulfate-containing pharmaceutical compositions

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090304819A1 (en) * 2002-06-19 2009-12-10 Gabriel Gojon-Romanillos Systemic Treatment of Pathological Conditions Resulting from Oxidative Stress and/or Redox Imbalance

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GREBOW, J: "Tablets and Capsules: Special Delivery.", 1 December 2010 (2010-12-01), pages 1, XP055277032, Retrieved from the Internet <URL:http//wwwnutritionaloutlookcom/article/tablets-and-capsules-special-delivery> [retrieved on 20140902] *
See also references of EP2949332A4 *

Also Published As

Publication number Publication date
EP2949332A4 (en) 2016-07-27
JP2016508996A (ja) 2016-03-24
BR112015017440A2 (pt) 2017-07-11
HK1217175A1 (zh) 2016-12-30
EP2949332A2 (en) 2015-12-02
CN105228633A (zh) 2016-01-06
MX2015009403A (es) 2017-07-04
AU2014210447A1 (en) 2015-08-20
WO2014116097A2 (es) 2014-07-31
KR20160140331A (ko) 2016-12-07
CA2898596A1 (en) 2014-07-31

Similar Documents

Publication Publication Date Title
WO2014116097A3 (es) Composiciones para tratamiento sistémico de condiciones patológicas resultantes de estrés oxidativo y/o desequilibrio redox
BR112015023747A2 (pt) métodos para tratar inflamação, doenças autoimunes e dor
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
MX365950B (es) Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica.
MA38060A1 (fr) Imidazo[1,2-a]pyridincarboxamides amino-substitués et leur utilisation
WO2014113429A3 (en) Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
WO2012092458A3 (en) Compositions comprising placental stem cells and platelet rich plasma, and methods of use thereof
EA201491330A1 (ru) Терапевтически активные соединения и способы их использования
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
EA201491819A1 (ru) Фармацевтические композиции для комбинированного лечения
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
MX362185B (es) Composiciones y tratamiento para enfermedades y trastornos del ojo.
EA201290041A1 (ru) Лечение расстройств, связанных с макрофагами
MA47356A1 (fr) Dérivés d&#39;isochromène utiles en tant qu&#39;inhibiteurs des phosphoinositide 3-kinases
EA201170349A1 (ru) Модуляторы mif
CL2008000592A1 (es) Compuestos derivados de pirrol sustituido, supresores de la secrecion de acidos; composicion farmaceutica; y uso en el tratamiento o profilaxis en enfermedades tales como ulcera peptica, gastritis, esofagitis, entre otras.
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201400392A1 (ru) ПРОИЗВОДНЫЕ 6-ЗАМЕЩЕННЫХ ТРИАЗОЛОПИРИДАЗИНОВ КАК АГОНИСТЫ Rev-Erb
TR201904980T4 (tr) Bir B-Raf inhibitörü, bir EGFR inhibitörü ve isteğe bağlı olarak bir PI3K-alfa inhibitörü içeren farmasötik kombinasyonlar.
EA201491857A1 (ru) АЛЛОСТЕРИЧЕСКИЕ МОДУЛЯТОРЫ α7 НИКОТИНОВОГО ХОЛИНОРЕЦЕПТОРА, ИХ ПРОИЗВОДНЫЕ И ИХ ПРИМЕНЕНИЕ
DK2714888T3 (da) Rekombinant gær
PH12015501002A1 (en) Treatment of cancer with pomalidomide in a renally impaired subject
WO2014210037A3 (en) A composition of mesenchymal stem cells
WO2015099838A3 (en) Compositions and methods of treating ocular diseases
MA38925A1 (fr) Dérivés de phénylalanine substitués

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201480018525.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14743853

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2898596

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/A/2015/009403

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015555120

Country of ref document: JP

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112015017440

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: 2014743853

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2014210447

Country of ref document: AU

Date of ref document: 20140128

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20157023387

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 112015017440

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20150722